December 30, 2015 - The court dismissed the case with prejudice.
June 26, 2015 - Defendants filed a motion to dismiss.

May 8, 2015 - The lead plaintiff filed a consolidated complaint on behalf of investors who purchased Galectin Therapeutics Inc (NASDAQ: GALT) common shares between October 25, 2013 and July 28, 2014. The lead plaintiff alleges that the defendants violated the Securities Exchange Act of 1934 by issuing false and misleading statements between October 25, 2013 and July 28, 2014.

March 24, 2015 - The lead plaintiff and lead counsel were appointed and all cases were consolidated.

January 21, 2015 - Cases were consolidated and transferred to the U.S. District Court for the Northern District of Georgia.

September 29, 2014 - Lead plaintiff motions were filed.

July 30, 2014 - An investor in shares of of Galectin Therapeutics Inc (NASDAQ: GALT) filed a lawsuit in the U.S. District Court for the District of Nevada against Galectin Therapeutics Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between January 6, 2014 and July 28, 2014.

According to the complaint the plaintiff alleges on behalf of purchasers of Galectin Therapeutics Inc (NASDAQ: GALT) common shares between January 6, 2014 and July 28, 2014, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between January 6, 2014 and July 28, 2014 defendants violated the federal securities laws by disseminating allegedly false and misleading statements to the investing public about the Company’s business and prospects and that as a result of defendants’ statements, Galectin Therapeutics Inc’s stock traded at allegedly artificially inflated prices between January 6, 2014 and July 28, 2014, reaching a high of $18.30 per share on February 27, 2014.

Shares of Galectin Therapeutics Inc (NASDAQ: GALT) grew from $1.67 per share in November 2012 to as high as $18.30 per share in February 2014.

On July 24, 2014, Emerging Growth Corp. claimed in a press release that Galectin Therapeutics Inc was “nipping at [the] heels” of its competitors and “actually may be closer than what first appears with a Phase 1 trial because of the potential to treat fatty liver disease even once it has progressed.” Then, on July 28, 2014, an article on SeekingAlpha.com claimed that Galectin Therapeutics Inc had “strong ties to stock promoters” engaging in a misleading brand awareness campaign aimed at boosting its stock price. The same day, a separate article on TheStreet.com revealed that Emerging Growth, through its parent company TDM Financial, a penny-stock promotions firm, was the investor relations and marketing company Galectin Therapeutics Inc was paying for misleading promotional campaigns to entice investors to buy its stock. Shares of Galectin Therapeutics Inc (NASDAQ: GALT) declined from $15.32 per share on July 25, 2014, to as low as $5.06 per share on August 8, 2014.